Last reviewed · How we verify

Mixed bipolar I disorder — Treatment Landscape & Competitive Intelligence

Mixed bipolar I disorder (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Mixed bipolar I disorder, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Vraylar CARIPRAZINE AbbVie Atypical Antipsychotic [EPC] D(3) dopamine receptor 2015-01-01
Saphris ASENAPINE Hisamitsu Atypical Antipsychotic [EPC] 5-hydroxytryptamine receptor 2C 2009-01-01
Abilify aripiprazole Generic (originally Otsuka/BMS) Third-generation antipsychotic (D2 partial agonist) 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6 2002-11-15
Geodon ziprasidone Pfizer Inc. Atypical antipsychotic (second-generation) Aspartate aminotransferase, cytoplasmic, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A 2001-02-05
Risperdal risperidone Johnson & Johnson (Janssen) Atypical Antipsychotic [EPC] 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6 1993-12-29
Tegretol carbamazepine Novartis AG (originally Geigy) Mood Stabilizer [EPC] Frizzled-8, Nuclear receptor subfamily 1 group I member 2, Neuronal acetylcholine receptor; alpha2/beta4 1968-03-11
Zyprexa Zyprexa Washington University School of Medicine Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A
Zyprexa olanzapine Eli Lilly Atypical Antipsychotic [EPC] Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A
Carbamazepin Carbamazepin Enanta Pharmaceuticals, Inc Frizzled-8, Nuclear receptor subfamily 1 group I member 2, Neuronal acetylcholine receptor; alpha2/beta4
Risperdal Risperdal Ohio State University 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. AbbVie · 1 drug in Mixed bipolar I disorder
  2. Eli Lilly · 1 drug in Mixed bipolar I disorder
  3. Enanta Pharmaceuticals, Inc · 1 drug in Mixed bipolar I disorder
  4. Generic (originally Otsuka/BMS) · 1 drug in Mixed bipolar I disorder
  5. Hisamitsu · 1 drug in Mixed bipolar I disorder
  6. Johnson & Johnson (Janssen) · 1 drug in Mixed bipolar I disorder
  7. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 1 drug in Mixed bipolar I disorder
  8. Novartis AG (originally Geigy) · 1 drug in Mixed bipolar I disorder
  9. Ohio State University · 1 drug in Mixed bipolar I disorder
  10. Pfizer Inc. · 1 drug in Mixed bipolar I disorder
  11. Washington University School of Medicine · 1 drug in Mixed bipolar I disorder

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Mixed bipolar I disorder:

Cite this brief

Drug Landscape (2026). Mixed bipolar I disorder — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/mixed-bipolar-i-disorder. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing